Sign in

CIK 0001590750 · Large accelerated filer

Viridian Therapeutics, Inc.\DE

Sign in to watch
Ticker
VRDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
471187261
Phone
617.272.4600
Business address
221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
Former names
MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$348,194
in 1 filing

Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Tousignant Jennifer −$348K Chief Legal Officer sold 100% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-05-11 Fairmount Funds Management LLC Director Purchase +1,176,470 $17.00 $20.0M 5,090,928
2025-10-23 Fairmount Funds Management LLC Director Purchase +454,545 $22.00 $10.0M 3,914,458
2024-09-27 Beetham Thomas W. Chief Operating Officer Purchase +5,000 $23.41 $117K 6,000
2024-09-27 Mahoney Stephen F. President and CEO Purchase +21,400 $23.33 $499K 21,400
2024-09-13 Fairmount Funds Management LLC Director Purchase +1,600,000 $18.75 $30.0M 3,445,813
2024-01-22 Fairmount Funds Management LLC Director Purchase +476,190 $21.00 $10.0M 1,839,954
2023-04-12 Myers Scott Dunseth Chief Executive Officer Purchase +4,000 $25.37 $101K 259,500
2023-03-13 Myers Scott Dunseth Chief Executive Officer Purchase +5,500 $29.15 $160K 255,500
2022-08-17 Fairmount Funds Management LLC Director Purchase +425,531 $23.50 $10.0M 1,363,764
2021-09-23 Frazier Life Sciences Public Fund, L.P. 10% owner Purchase +200,000 $11.00 $2.2M 1,505,200
2021-09-21 Fairmount Funds Management LLC Director Purchase +909,000 $11.00 $10.0M 938,233

Page 1 of 1 · 11 trades